Nomathemba Chandiwana to Piperazines
This is a "connection" page, showing publications Nomathemba Chandiwana has written about Piperazines.
Connection Strength
1,608
-
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS. 2021 02 02; 35(2):205-211.
Score: 0,712
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
Score: 0,221
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,219
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
Score: 0,189
-
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
Score: 0,183
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,043
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,040